XOMA Royalty Corp.
NASDAQ:XOMABiotechnology
+$0.19 today
- Market cap
- $503.77M
- Beta
- 0.87
- P/E (TTM)
- 15.8
- EPS (TTM)
- $2.65
Volume 4.22M
Average 0.21M
XOMA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
XOMA Royalty Corp.NASDAQ: XOMA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $49K fell 96.2% year over year, behind the -88.7% change in trailing-twelve-month research & development. Sequentially, it fell 82.6% from the prior quarter. Over 3 fiscal years it compounded at +123.7% a year.
Context
- Research & development amounted to 3.3% of revenue in FY2025, down 6.8 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -96.2% toward the trailing-twelve-month pace of -88.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 1.71M USD
- Year-over-year change
- -40.5%
- 4-year CAGR
- +77.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.71M | -40.5% |
| FY2024 | 2024-12-31 | 2.88M | +1910.5% |
| FY2023 | 2023-12-31 | 143K | -6.5% |
| FY2022 | 2022-12-31 | 153K | -10.5% |
| FY2021 | 2021-12-31 | 171K | — |
Research & Development vs competitors
How XOMA compares with its peers on the latest reported figures
- XOMA's LTM Mar 2026 research & development of $468K is the lowest of the 10 companies compared; the peer median is $58.13M.
- Its year-over-year change of -88.7% is the lowest of 10, against a peer median of +1.2%.
- Research & development amounts to 1.3% of revenue for XOMA, versus a peer median of 1532.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $155.55M | +43.4% | +21.4% | — | |
| LTM Mar 2026 | $137.53M | -14.3% | -5.0% | — | |
| LTM Mar 2026 | $112.11M | -27.3% | +3.1% | 121.1% | |
| LTM Mar 2026 | $94.92M | +19.3% | +28.8% | — | |
| LTM Mar 2026 | $58.13M | +16.8% | +6.7% | — | |
| LTM Mar 2026 | $54.53M | -11.0% | -9.3% | 2944.3% | |
| LTM Mar 2026 | $26.95M | +28.1% | +46.4% | — | |
| LTM Mar 2026 | $19.2M | +1.2% | +17.6% | — | |
| LTM Mar 2026 | $10.04M | -71.3% | -23.4% | — | |
| LTM Mar 2026 | $468K | -88.7% | +123.7% | 1.3% | |
| Peer median (excluding XOMA) | $58.13M | +1.2% | +6.7% | 1532.7% | |
Competitors are the stored peer set for XOMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 38.16M | 6.03M | 4.76M | 28.49M | 52.15M |
| Cost of Revenue | 171K | 274K | 143K | 206K | 2.96M |
| Gross Profit | 37.99M | 5.75M | 4.62M | 28.28M | 49.18M |
| Gross Margin | 99.6% | 95.5% | 97.0% | 99.3% | 94.3% |
| Research & Development | 171K | 153K | 143K | 2.88M | 1.71M |
| Selling, General & Admin | 20.46M | 23.19M | 27.18M | 34.48M | 36.09M |
| Operating Expenses | 20.46M | 23.17M | 46.46M | 68.26M | 37.79M |
| Depreciation & Amortization | 167K | 274K | 900K | 216K | 2.97M |
| EBITDA | 16.52M | (16.85M) | (22.56M) | (5.42M) | 47.82M |
| EBITDA Margin | 43.3% | -279.5% | -474.2% | -19.0% | 91.7% |
| Operating Income | 17.53M | (17.41M) | (41.85M) | (39.98M) | 11.38M |
| Operating Margin | 45.9% | -288.9% | -879.5% | -140.3% | 21.8% |
| Interest Income | 0 | 694K | 0 | 0 | 0 |
| Interest Expense | 461K | 0 | 569K | 13.84M | 13.03M |
| Other Income / Expenses | (1.64M) | 295K | 1.02M | 20.5M | 20.43M |
| Income Before Tax | 15.89M | (17.12M) | (40.83M) | (19.48M) | 31.82M |
| Pre-Tax Margin | 41.6% | -284.0% | -858.2% | -68.4% | 61.0% |
| Income Tax Expense | 91K | (15K) | 0 | (5.66M) | 103K |
| Net Income | 15.8M | (17.1M) | (40.83M) | (13.82M) | 31.71M |
| Net Margin | 41.4% | -283.8% | -858.2% | -48.5% | 60.8% |
| EPS (Basic) | 0.69 | (1.98) | (4.04) | (1.65) | 1.53 |
| EPS (Diluted) | 0.65 | (1.98) | (4.04) | (1.65) | 1.46 |
| Weighted Avg Shares | 11.29M | 11.41M | 11.47M | 11.7M | 17.98M |
| Weighted Avg Shares (Diluted) | 12.19M | 11.41M | 11.47M | 11.7M | 17.98M |
XOMA Royalty Corp.
NASDAQ:XOMA
Intrinsic Alpha fair value
Locked
Current Price
$40.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.